SILVER SPRING
Hympavzi indication expanded for hemophilia A and B
- Sponsor
- Pfizer Inc. $PFE
- Drug
- Hympavzi · marstacimab-hncq
- Indication
- hemophilia A and B
FDA approved Pfizer's Hympavzi for additional hemophilia A and B patient populations based on significant medical need.
What this means
Hympavzi is an antibody drug that helps blood clot by blocking a natural protein that slows clotting, offering an alternative to traditional factor-replacement therapies for hemophilia. The FDA today expanded its approval to cover both hemophilia A and B patients, adding hemophilia B to its original clearance for hemophilia A. This gives more patients access to a weekly injection that may reduce bleeding episodes without needing frequent factor infusions.
Drug Watch — recent news on Hympavzi
- Marstacimab Supports Breakthrough Bleed Control in Hemophilia A or B - consultant360.com
- 데일리팜코리아, 데일리팜 영문뉴스, dailypharmkorea - 데일리팜
- Pfizer's hemophilia drug Hympavzi nears Korean reimbursement, challenges Hemlibra - koreabiomed.com
- BASIS KIDS Phase 3 Trial Releases Encouraging Interim Data on Marstacimab for Hemophilia A, B - Docwire News
- Scientists screened thousands of molecules to develop Hympavzi - Hemophilia News Today